January 2, 2024 4:43pm

On Novartis (NVS +$0.03 or+ 0.03%) sweetening Voyager Therapeutics (VYGR +$0.56 or +6.64% to $9.00) licensing news with $100 million upfront

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Pre-open Indication Results: 3 Hits and 2 Miss

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi provides the extenuating factors of share pricing.

Never leave an investor uninformed! A trusted source of factual reporting!

With no sigh of relief, I try to answer or qualify one question, in which company should investors put, keep and commit their money

Ask yourself, do you know why you own certain equities?

 

Tuesday: The Dow closed UP +25.50 points or +0.07%, the S&P closed DOWN -27 points or -0.57% while the Nasdaq closed DOWN -245.41 points or -1.63%

Monday was New Years Day

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

indexes closed mixed with the S&P and Nasdaq dived Tuesday, the first trading day of the year, as U.S. Treasury yields climbed, interest rates rebounded slightly and investors took money off the table following a strong 2023.

Volume rose on the Nasdaq as compared to the same time on Friday.

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

Tuesday’s advance/decline line was positive at the open with 27 incliners, 6 decliners and 2 flats, ending with a positive close of 21 incliners, 14 decliners and 0 flat

Monday was a holiday

Economic Data Docket: U.S. construction spending rose less than expected in November amid a decline in outlays on public projects. However, data for the prior month was revised sharply higher suggesting underlying strength in the sector.

 

Pre-open Indications: 3 Hits <Ionis Pharmaceuticals (IONS +$2.28), Blueprint Medicine (BPMC -$1.17), MiMedx (MDXG -$0.90)> and 2 Miss <Prime Medine (PRME -$0.10), CRISPR Therapeutics (CRSP +$3.46)>

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q1/24: 1 holiday and 1 positive close

Q4: 

  • 1 holiday, 10 negative and 10 positive closes
  • November – 11 positives, 1 holiday and 10 negative closes
  • October – 12 negative and 10 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was up +1.63% and the XBI was up +1.03%
  • Monday was holiday

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +0.83 point or +6.67% at 13.28
  • Monday was Christmas

 

Tuesday’s Closing Down (10 of 14):

  • Blueprint Medicine (BPMC -$1.17 after Monday’s holiday and Friday’s +$0.89),
  • MiMedx (MDXG -$0.90),
  • Vericel (VCEL -$0.73),
  • Harvard Apparatus GN (HRGN -$0.48),
  • BioLife Solutions (BLFS -$0.27 after Monday’s holiday and Friday’s -$0.47),
  • Caribou Biosciences (CRBU -$1.16),
  • Editas Medicine (EDIT -$0.15),
  • Prime Medine (PRME -$0.10 after Monday’s holiday and Friday’s -$0.69)
  • Compass therapeutics (CMPX -$0.08 after Monday’s holiday and Friday’s +$0.07),
  • Fate Therapeutics (FATE -$0.05)

Tuesday’s Closing Up (10 of 21):

  • Alnylam Pharmaceuticals (ALNY +$3.52 after Monday’s holiday and Friday’s -$4.30),
  • CRISPR Therapeutics (CRSP +$3.46 after Monday’s holiday and Friday’s -$1.70),
  • Ionis Pharmaceuticals (IONS +$2.28 after Monday’s holiday and Friday’s +$0.09),
  • Sage Therapeutics (SAGE +$0.81),
  • Voyager Therapeutics (VYGR +$0.56),
  • Regenxbio (RGNX +$ after Monday’s holiday and Friday’s -$0.59),
  • Ultragenyx Pharmaceuticals (RARE +$0.35 after Monday’s holiday and Friday’s -$0.45),
  • Intellia Therapeutics (NTLA +$0.33 after Monday’s holiday and Friday’s -$1.28),
  • Generation Bio (GBIO +$0.21),
  • Beam Therapeutics (BEAM +$0.19 after Monday’s holiday and Friday’s -$2.21),

 

Q1/24 – January

  • Tuesday closed positive with 21 incliners, 14 decliners and 0 flat

 

The BOTTOM LINE: as I had written this a.m., “12/29/23 ended with my message of: “Looking toward 2024 with one word – recalibration i.e., a change in the way you do or think about something – markets and the cell and gene therapy sector.”

  • We are back on the merry-go-round or did we ever get off as the music swayed.

I also wrote, “There could be some wobbles in early January, as volume returns and some tax selling takes place. So, investors may want to see how that shakes out. But they should be looking for new buying opportunities, and reviewing past trades.”

  • “News, financings, Q4 earnings LPS (loss-per-share) and “runways” will be the under-current or headwind for January through March 2024. Pricing for gene therapies will continue to dominate share ascensions and downfalls!” <me>

 

Tuesday’s backdrop:

  • “Indexes fell as market optimism that the Federal Reserve can engineer a soft landing as it cuts interest rates this year lost a bit of luster. <Reuters>
  • The U.S. benchmark's yield last week traded as low as 3.783%, or more than the 150 basis points of rate cuts the futures have priced in by next December for the Fed's target interest rate as the market weighs the economic outlook.

 

Interesting quote, “The biggest concern is whether the market misinterprets slowing growth as a warning sign for a looming recession. <Jack Janasiewicz, portfolio manager and lead portfolio strategist at Natixis Investment Managers Solutions in Boston>

 

The top three (3) performing in the session:

  • Tuesday: CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS)
  • Monday; Holiday

The worst three (3) in the session:

  • Tuesday: MiMedx (MDXG), Blueprint Medicine (BPMC) and Vericel (VCEL)
  • Monday: holiday

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.